Critical appraisal of a quadrivalent CRM₁₉₇ conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo^®) in the context of treatment and prevention of invasive disease

Figures & data

Table 1 Antibiotic recommendations for treating and preventing invasive meningococcal disease³¹

Region	Therapy recommended	Duration (days)	Alternative therapies
US	Penicillin G, ampicillin, third-generation cephalosporin	5–7	Chloramphenicol,* meropenem, fluoroquinolone
Canada	Penicillin G	5–7	Not specified
Europe	Benzyl penicillin, third-generation cephalosporin	5–7	Chloramphenicol,* meropenem, moxifloxacin

Note:

* In cases of penicillin allergy.

Table 2 Overview of published clinical studies of MenACWY-CRM in children and adolescents

Age group	Immunogenicity among MenACWY-CRM recipients	Safety and tolerability among MenACWY-CRM recipients
Infants from 2 months of age*	60%–92% of two-dose and 81%–99% of three-dose recipients had protective hSBA titers (≥4)^Citation52	Most common reactions were injection site redness and irritability^Citation52
Infants from 6 months of age	86%–100% of two-dose recipients had protective hSBA titers (≥4)^Citation54	Most common reactions were injection site redness and irritability^Citation54
Toddlers	86%–100% of two-dose primed and 94%–100% of three-dose primed toddlers had protective hSBA titers (≥4)^Citation52	Most common reactions were injection site redness and irritability^Citation52
	65%–100% of unprimed toddlers had protective hSBA titers (≥4) after two doses^Citation54
Children aged 2–10 years	83%–95% of two-dose recipients had protective hSBA titers (≥4)^Citation56	Most common reactions were injection site pain, headache, and irritability^Citation56
Adolescents	75%–96% of adolescents had protective hSBA titers (≥4)^Citation58,Citation59	Most common reactions were injection site pain and headache^Citation58,Citation59

Note:

* Used an adjuvant vaccine formulation.

Abbreviation: hSBA, human complement.

Figure 1 Percent of children aged 2–10 years with seroresponse 30 days following a single dose of MenACWY-D or MenACWY-CRM.

Figure 2 Percent of children aged 2–5 years reporting solicited injection site reactions within the 7 days following a single dose of MenACWY-D (n = 684) or MenACWY-CRM (n = 693).

Figure 3 Percent of children 6–10 years reporting solicited injection site reactions within the 7 days following a single dose of MenACWY-D (n = 571) or MenACWY-CRM (n = 582).

De GaudioMChiappiniEGalliLDe MartinoMTherapeutic management of bacterial meningitis in children: a systematic review and comparison of published guidelines from a European perspectiveJ Che mother2010224226237

 Google Scholar

VesikariTCeddiaFKarvonenAImmune response and immunological memory induced by a novel meningococcal ACWY-CRM conjugate vaccine (MenACWY) in toddlersPresented at the 23rd annual meeting of the European Society for Paediatric Infectious DiseasesValencia, SpainMay 18–20, 2005

 Google Scholar

KleinNGillCJBedellLPivotal safety and immunogenicity of an investigational quadrivalent meningococcal vaccine (MenACWY-CRM; Menveo®) in 4545 infantsPresented atthe annual meeting of the Infectious Diseases Society of AmericaVancouver, CanadaOctober 21–24, 2010

 Google Scholar

BlackSKleinNPShahJImmunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2–10 years of ageVaccine201028365766319895922

 PubMed Web of Science ®Google Scholar

JacksonLAJacobsonRMReisingerKSA randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescentsPediatr Infect Dis J2009282869119116603

 PubMed Web of Science ®Google Scholar

JacksonLABaxterRReisingerKPhase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescentsClin Infect Dis2009491e1e1019476428

 PubMed Web of Science ®Google Scholar